Floatz logo

Tabelecleucel

Epstein-Barr Virus Infection

Pierre Fabre MedicamentCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Epstein-Barr Virus Infection cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Jennifer Amengual
Phase 2BB
L-Dep
Beijing Friendship Hospital
Phase 3B
Bortezomib
Massachusetts General Hospital
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Baltaleucel-T
Cell Medica Ltd
Phase 2CCC

View all 16 →

Same molecule, other indications

Tabelecleucel is also rated in:

Epstein-Barr virus-associated lymphoproliferative disorderDormant
BB
Indicative ·
66 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →
Solid Organ Transplant ComplicationsDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →